197 related articles for article (PubMed ID: 4693654)
1. Hypocomplementemia of membranoproliferative nephritis. Dependence of the nephritic factor reaction on properdin factor B.
Ruley EJ; Forristal J; Davis NC; Andres C; West CD
J Clin Invest; 1973 Apr; 52(4):896-904. PubMed ID: 4693654
[TBL] [Abstract][Full Text] [Related]
2. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
Perrin LH; Lambert PH; Miescher PA
J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431
[TBL] [Abstract][Full Text] [Related]
3. Formation in the presence of C3 nephritic factor (C3NeF) of an alternative pathway C3 convertase containing uncleaved B.
Daha MR; Fearon DT; Austen KF
Immunology; 1976 Nov; 31(5):789-96. PubMed ID: 992711
[TBL] [Abstract][Full Text] [Related]
4. Complement activation in semisolid media: insolubilization of alternative pathway convertases in agar gels with C3 nephritic factor-containing sera.
Arnaout MA; Davis AE; Rosen RS; Alper CA
J Immunol; 1977 Oct; 119(4):1316-20. PubMed ID: 894039
[TBL] [Abstract][Full Text] [Related]
5. Interaction of zymosan and of activated properdin with factor D-depleted guinea pig serum: implications for the mechanism of initial C3 cleavage via the alternative complement pathway.
Brade V; Bentley C; Bitter-Suermann D; Hadding U
Z Immunitatsforsch Immunobiol; 1977 Feb; 152(5):402-14. PubMed ID: 556571
[TBL] [Abstract][Full Text] [Related]
6. Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis.
Schena FP; Pertosa G; Stanziale P; Vox E; Pecoraro C; Andreucci VE
Clin Nephrol; 1982 Nov; 18(5):240-6. PubMed ID: 7151338
[TBL] [Abstract][Full Text] [Related]
7. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.
Daha MR; Fearon DT; Austen KF
J Immunol; 1976 Jan; 116(1):1-7. PubMed ID: 1245733
[TBL] [Abstract][Full Text] [Related]
8. Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF.
Tanuma Y; Ohi H; Hatano M
Clin Immunol Immunopathol; 1990 Aug; 56(2):226-38. PubMed ID: 2143128
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of a non-complement-dependent C3-reactive complex formed form factors in nephritic and normal serum.
Vallota EH; Forristal J; Spitzer RE; Davis NC; West CD
J Exp Med; 1970 Jun; 131(6):1306-24. PubMed ID: 4192571
[TBL] [Abstract][Full Text] [Related]
10. Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis.
Hiramatsu M; Balow JE; Tsokos GC
J Immunol; 1986 Jun; 136(12):4451-5. PubMed ID: 3011894
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of activation of the properdin system. Studies on properdin electrophoretic mobility in agarose activation of the alternative pathway.
Adam C; Williams DG; Peters DK
Clin Exp Immunol; 1975 Nov; 22(2):240-8. PubMed ID: 813932
[TBL] [Abstract][Full Text] [Related]
12. The effect of anticomplementary substances on properdin in normal and C2-deficient sera.
McLean RH; Townsend K; Michael AF
Clin Exp Immunol; 1975 Mar; 19(3):435-44. PubMed ID: 1204244
[TBL] [Abstract][Full Text] [Related]
13. A serum C3-activating factor: its characterization and its presence in glomerular deposits.
Roberts JL; Levy M; Chioros PG; Bartlow BG; Forristal J; West CD; Habib R; Lewis EJ
J Immunol; 1981 Sep; 127(3):1131-7. PubMed ID: 7021675
[TBL] [Abstract][Full Text] [Related]
14. Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid.
Vogt W; Schmidt G; Lynen R; Dieminger L
J Immunol; 1975 Feb; 114(2 Pt 1):671-7. PubMed ID: 804510
[TBL] [Abstract][Full Text] [Related]
15. Studies of the alternate pathway in chelated serum.
Forsgren A; Mclean RH; Michael AF; Quie PG
J Lab Clin Med; 1975 Jun; 85(6):904-12. PubMed ID: 805816
[TBL] [Abstract][Full Text] [Related]
16. [Chronic urticaria and acquired complement deficiency due to a nephritic factor (C3NeF)].
Borradori L; Rybojad M; Weiss L; Späth P; Puissant A; Morel P
Schweiz Med Wochenschr; 1990 Aug; 120(34):1236-41. PubMed ID: 2218445
[TBL] [Abstract][Full Text] [Related]
17. Serum factors activating the alternative complement pathway in autoimmune disease: description of two different factors from patients with systemic lupus erythematosus.
Arroyave CM; Wilson MR; Tan EM
J Immunol; 1976 Mar; 116(3):821-6. PubMed ID: 815434
[TBL] [Abstract][Full Text] [Related]
18. A serum factor in chronic hypocomplementemic hephritis distinct from immunoglobulins and activating the alternate pathway of complement.
Vallota EH; Götze O; Spiegelberg HL; Forristal J; West CD; Müller-Eberhard HJ
J Exp Med; 1974 May; 139(5):1249-61. PubMed ID: 4207623
[TBL] [Abstract][Full Text] [Related]
19. Selective disappearance of C3NeF IgG autoantibody in the plasma of a patient with membranoproliferative glomerulonephritis following renal transplantation.
Frémeaux-Bacchi V; Weiss L; Brun P; Kazatchkine MD
Nephrol Dial Transplant; 1994; 9(7):811-4. PubMed ID: 7970124
[TBL] [Abstract][Full Text] [Related]
20. Evidence for the presence of components of the alternative (properdin) pathway of complement activation in respiratory secretions.
Robertson J; Caldwell JR; Castle JR; Waldman RH
J Immunol; 1976 Sep; 117(3):900-3. PubMed ID: 956659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
